期刊文献+

多发性骨髓瘤的临床及全身磁共振分析 被引量:13

The clinic and whole-body analysis of multiple myeoma by MRI
下载PDF
导出
摘要 目的:分析多发性骨髓瘤的临床特征及其全身磁共振表现,探讨全身磁共振分期与临床分期之间的关系。方法:采用Siemens 3.0T磁共振对15例经病理证实的多发性骨髓瘤患者进行全身检查。采用Fisher精确概率法对磁共振及临床两种分期方法进行分析。结果:多发性骨髓瘤最常见的临床表现有骨痛、贫血、乏力、肝脾肿大和浅表淋巴结肿大等;15例患者中全身磁共振表现为正常型4例,弥漫型3例,局灶型3例,混合型4例,胡椒面型1例。磁共振分期为Ⅰ期4例,Ⅱ期3例,Ⅲ期8例,临床分期为Ⅰ期1例,Ⅱ期4例,Ⅲ期10例。两种分期方法进行统计学分析得出P=0.46>0.05。结论:多发性骨髓瘤临床表现多样化,主要表现为骨痛;全身磁共振成像对于多发性骨髓瘤具有较好的成像效果和评估价值;两种分期方法之间没有统计学差异。 Objective:To analyze the clinical manifestations of multiple myeloma and the images of whole-body magnetic resonance,to explore the relationship between MRI stage and clinical stage.Methods:15 multiple myeloma patients enrolled.Histological proof of multiple myeloma was obtained in all cases.Fisher exact test is used to analyze MRI stage and clinical stage.Results:The most common clinical manifestations of multiple myeloma are bone pain,fatigue,anemia,and hepatosplenomegaly and superficial lymphadenopathy.15 cases were classified as normal type(4 cases),diffuse type(3 cases),focal type(3 cases),mixed type(4 cases) and "salt and pepper" type(1 case).Conclusion:Multiple myeloma's clinical manifestations is divergent,the most common is bone pain.Whole-body MR has good image effects and evaluation value for multiple myeloma.And,there is no statistical significant difference between MRI stage and clinical stage.
出处 《医学影像学杂志》 2011年第1期98-102,共5页 Journal of Medical Imaging
关键词 多发性骨髓瘤 全身磁共振成像 Whole-body magnetic resonance(WB MR) Multiple myeloma(MM)
  • 相关文献

参考文献4

二级参考文献23

  • 1李守静,李宏然,赵相印,李清朗.多发性骨髓瘤诊断的探讨(附2547例分析)[J].中华肿瘤杂志,1995,17(1):43-46. 被引量:151
  • 2肖志坚,郝玉书.免疫表型分析与急性白血病诊断[J].中华血液学杂志,1997,18(1):53-54. 被引量:67
  • 3武永吉 张安.骨髓瘤前期2例[J].中华内科杂志,1992,31:545-546.
  • 4Schirrmeister H, Bommer M, Buck AK, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET[J]. Eur J Nucl Med, 2002, 29(3): 361-366.
  • 5EI-Shirbiny AM, Yeung H, Imbriaco M, et al. Technetium99m-MIBI versus fluorine-18 FDG in diffuse multiple myeloma[J]. J Nucl Med, 1997, 38(8): 1208-1210.
  • 6Orchard K, Barrington S, Buscombe J, et al. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma [J]. Br J Hematol, 2002, 117(1): 133-135.
  • 7Pace L, Catalano L, Del Vecchio S, et al. Predictive value of technetium-99m seatamibi in patients with multiple myeloma and potential role in the follow-up [J]. Eur J Nucl Med,2001, 28(3): 304-312.
  • 8Alexandrakis MG, Kyriakou DS, Passam F, et al. Value of Tc-99m seatamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate[J]. Ann hematol, 2001, 80(6): 349-353.
  • 9Watanabe N, Shimizu M, Kageyama M, et al. Multiple myelomaevaluated with 201TI scintigraphy compared with bone scintigraphy[J]. J Nucl Med, 1999, 40(7): 1138-1142.
  • 10Ishibashi M, Nonoshita M, Uchida M, et al. Bone marrow uptake of thaUium-201 before and after therapy in multiple myeloma[J]. J Nucl Med, 1998, 39(3): 473-475.

共引文献106

同被引文献103

引证文献13

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部